KLWA
GCVRZ

Kelly Lawrence W & Associates’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Kelly Lawrence W & Associates’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed – – 228
2017
Q1 		$0 Buy
+3
New +$1 ﹤0.01% 240

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Kelly Lawrence W & Associates's GCVRZ Position: Q2 2017 in Review

Kelly Lawrence W & Associates sold out of Sanofi Contingent Value Rights (GCVRZ) in Q2 2017, closing a stake of 3 shares.

Kelly Lawrence W & Associates first reported a position in GCVRZ in Q1 2017 and held it in 1 quarter. The position peaked at $0 in Q1 2017. 115 funds tracked by Wall St. Rank hold GCVRZ as of Q2 2017.

  • Kelly Lawrence W & Associates reported no remaining Sanofi Contingent Value Rights position as of Q2 2017 after selling out during the quarter.
  • Kelly Lawrence W & Associates sold 3 Sanofi Contingent Value Rights shares in Q2 2017.
  • Kelly Lawrence W & Associates first reported a position in Sanofi Contingent Value Rights in Q1 2017 and held it in 1 quarter.
  • Kelly Lawrence W & Associates's Sanofi Contingent Value Rights position peaked at $0 in Q1 2017.
  • 115 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q2 2017.

Based on Kelly Lawrence W & Associates's 13F filing for Q2 2017, filed 1 Aug 2017.